(Z)-5-(1-methyl-1-phenylmethylene)-2,4-thiazolidinedione | 291536-37-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-5-(1-methyl-1-phenylmethylene)-2,4-thiazolidinedione
• 英文别名: 5-(1-Phenylethylidene)thiazolidine-2,4-dione；(5Z)-5-(1-phenylethylidene)-1,3-thiazolidine-2,4-dione
• CAS: 291536-37-3
• 化学式: C₁₁H₉NO₂S
• 分子量: 219.264
• InChiKey: YLTRHCGCTZECOC-CLFYSBASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-5-(1-methyl-1-phenylmethylene)-2,4-thiazolidinedione 在 吡啶 、 锂硼氢 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以85%的产率得到5-(1-phenylethyl)-2,4-thiazolidinedione
  参考文献：
  名称：

  Regiospecific Reduction of 5-Benzylidene-2,4-Thiazolidinediones and 4-Oxo-2-thiazolidinethiones using Lithium Borohydride in Pyridine and Tetrahydrofuran

  摘要：

  The novel regiospecific and general reduction of 5-benzylidene-2,4-thiazolidinediones and 5-benzylidene-4-oxo-2-thiazolidinethiones to the corresponding 5-benzyl derivatives has been accomplished using lithium borohydride in pyridine and tetrahydrofuran. Sodium borohydride and lithium chloride can also be used under these conditions, which represents a cheaper alternative to lithium borohydride. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(00)00361-6
• 作为产物：
  描述：

  2,4-噻唑烷二酮 、 苯乙酮 在 溶剂黄146 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以51%的产率得到(Z)-5-(1-methyl-1-phenylmethylene)-2,4-thiazolidinedione
  参考文献：
  名称：

  Regiospecific Reduction of 5-Benzylidene-2,4-Thiazolidinediones and 4-Oxo-2-thiazolidinethiones using Lithium Borohydride in Pyridine and Tetrahydrofuran

  摘要：

  The novel regiospecific and general reduction of 5-benzylidene-2,4-thiazolidinediones and 5-benzylidene-4-oxo-2-thiazolidinethiones to the corresponding 5-benzyl derivatives has been accomplished using lithium borohydride in pyridine and tetrahydrofuran. Sodium borohydride and lithium chloride can also be used under these conditions, which represents a cheaper alternative to lithium borohydride. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(00)00361-6

文献信息

• Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand
  申请人：Kaarsholm Niels Christian

  公开号：US20090123563A1

  公开（公告）日：2009-05-14

  Novel preparations comprising branched ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer. The preparations have a prolonged action designed for flexible injection regimes.

  这段话的中文翻译如下：使用分支配体的新型制备物，用于R-状态胰岛素六聚体的HisB10 Zn2+位点。这些制备物具有长效作用，旨在为灵活的注射方案设计。
• CHARGE CONTROL AGENT AND TONER USING SAME
  申请人：Hodogaya Chemical Co., Ltd.

  公开号：EP2618218A1

  公开（公告）日：2013-07-24

  The present invention provides a charge control agent containing, as an active substance(s), one or two or more thiazolidinedione derivatives represented by the following formula (1), where R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, a linear or branched alkyl group having 1 to 8 carbon atoms which may have a substituent, etc.; R3 to R7, which may be identical to or different from each other, represent a hydrogen atom, a chlorine atom, a linear or branched alkyl group having 1 to 8 carbon atoms which may have a substituent, a linear or branched alkenyl group having 2 to 6 carbon atoms which may have a substituent, a linear or branched alkyloxy group having 1 to 8 carbon atoms which may have a substituent, etc., and may be joined to each other to form a ring; and V, W, X, Y and Z represent a carbon atom or a nitrogen atom, and 0 to 3 of any of V, W, X, Y and Z are nitrogen atoms which do not have the substituents of R3 to R7.

  本发明提供了一种电荷控制剂，其活性物质含有一种或两种以上由下式（1）表示的噻唑烷二酮衍生物、 其中 R1 代表氢原子等；R2 代表氢原子、具有 1 至 8 个碳原子的直链或支链烷基，可带有取代基等。R3 至 R7 可相互相同或不同，分别代表氢原子、氯原子、具有 1 至 8 个碳原子且可能具有取代基的直链或支链烷基、具有 2 至 6 个碳原子且可能具有取代基的直链或支链烯基、具有 1 至 8 个碳原子且可能具有取代基的直链或支链烷氧基等、V、W、X、Y 和 Z 代表碳原子或氮原子，V、W、X、Y 和 Z 中的 0 至 3 个氮原子不含 R3 至 R7 的取代基。
• NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
  申请人：NOVO NORDISK A/S

  公开号：EP1429763B1

  公开（公告）日：2007-05-30
• PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER
  申请人：NOVO NORDISK A/S

  公开号：EP1585541B1

  公开（公告）日：2007-11-14
• US7879893B2
  申请人：——

  公开号：US7879893B2

  公开（公告）日：2011-02-01